Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study

Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study

Introduction: In the CAPITAL study, a randomized phase 3 study, wherein carboplatin plus nab-paclitaxel treatment was compared with docetaxel treatment for older patients with squamous-cell lung cancer, the former became the new standard of care for such patients. Our study aimed to evaluate whether...

Full description

Bibliographic Details
Main Authors: Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:JTO Clinical and Research Reports
Subjects:
Squamous-cell non–small cell lung cancer
Elderly
Immune checkpoint inhibitors
Nab-paclitaxel
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432300053X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432300053X

Similar Items